Abstract C174: Examining cervical cancer screening rates among women living with HIV in Kajiado County, Kenya

Abstract Background: Kenyan women are disproportionately affected by HIV than their male counterparts, with a prevalence 5.5% compared to men whose prevalence is 2.9%. Women living with HIV (WLHIV) are more susceptible to cancer, in particular HPV-related cancers due to their immune-compromised status. In response, Kenyan Health Ministry recommends that women living with HIV (WLWH) be screened for cervical cancer annually by either visual inspection with acetic acid (VIA) or visual inspection with Lugol’s iodine (VILI), cytology and testing for HPV once every two years. Objective: Examining the rate of cervical cancer screening among women living with HIV (WLWH) in Kajiado County in 2022. Methodology: The electronic health information system was used to abstract data for WLWH in Kajiado county with 57 antiretroviral (ART) facilities. However, our analysis accessed data from 38 facilities whose data is captured in the health information system. Authorized health care workers from the County were requested to abstract redacted data from the health information system. No personal identifiers were collected from the system as away of protecting the privacy of individuals and abiding with the Kenya’s data protection law. Authorization to access the county was obtained from the county’s department of health while ethical approval was obtained from Mount Kenya University’s Institutional Scientific and Ethics Review Committee. Results: In 2022, a total of 16,827 people living with HIV were enrolled for care at the 38 ART selected sites. 11,785 (70%) were women with an age range of 15 to 49 years. A total of 3342 WLWH, representing 28.36% of the target population, were screened by using VIA. Of those screened, 3240 (97%) tested negative, 78 (2.3%) had positive results while 24 (0.7%) had suspicious lesions. Conclusion: Our analysis shows low reach of cervical cancer screening with only 28.36% of the targeted women being screened in 2022. The only available testing method (VIA) is less robust as compared to cytology and HPV testing. Thus, cervical cancer screening is underutilized, and importantly the available screening suffers fromWe also found a gap in reporting of HPV testing in the county. We thus recommend implementation science with community engagement examining the barriers to cervical cancer screening and HPV testing as well as timely reporting from multistakeholder e.g., system, provider, patient, family and advocate perspectives. This multisectoral health system-services approach will better inform research, practice and policy for effective HPV-related cancer prevention and control to reduce cancer-related morbidity and mortality among WLWH,. Citation Format: Caren Kamau, MS, Alice Njoroge,MS, Francis Makokha,PhD, Kimlin Ashing,PhD. Examining cervical cancer screening rates among women living with HIV in Kajiado County, Kenya [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr C174.